Mitolytix Novel Biomolecule Converts Malignant Phenotype to Benign Status
A new biomolecule developed my Mitolytix Research, referred to as a "Catalyst," significantly induce necrosis of malignant tumors without histological changes in adjacent nontumorous tissue. The objective is tumor “normalization,” in contrast to “expeditious tumor destruction.” While some similarities between the tumor response of chemo-radiotherapy and the catalyst are observed, several differences are noted. - April 17, 2021
Mitolytix: Innovative Biomolecule to Treat Cancer Shows Promise in Early Studies
Mitolytix Research Ltd.(TM) is a private company dedicated to developing innovative cancer treatments. - March 17, 2021
Press Releases 1 - 2 of 2